4results about How to "Inhibit phosphorylation" patented technology

The application discloses a method for efficiently separating high-purity conjugated linoleic acid from Tetrastigma hemsleyanum, which takes stems and leaves of Tetrastigma hemsleyanum as raw materials, and sequentially carries out ethanol extraction, ethyl acetate extraction, normal-phase silica gel column chromatography, gel column chromatography and semi-preparative reverse-phase liquid chromatography coupling purification process, so that 10E, 12Z-CLA monomers with chemical purity of greater than or equal to 99% are efficiently prepared. Experiments prove that the compound can significantly inhibit the inflammatory reaction of macrophages induced by lipopolysaccharide, and the mechanism is that the compound down-regulates TLR4 protein expression and inhibits NF-kappa B p65 phosphorylation, so as to block the activation of the TLR4 / NF-kappa B signal pathway. The application realizes high-value utilization of the abandoned resources of Tetrastigma hemsleyanum, and the obtained product can be used as a definite active ingredient for developing anti-inflammatory drugs, functional foods or cosmetics.

The present application relates to the technical field of biology, and particularly discloses a kind of tyrosine iodination modified PP2A protein monoclonal antibody, preparation method and application.The present application is prepared by tyrosine iodination modified PP2A protein antigen peptide, rabbit is immunized to prepare monoclonal antibody, and is selected by phage display technology, expression vector amplification and ELISA screening, finally obtains a strain of monoclonal antibody R004 that can effectively recognize target.The antibody shows good sensitivity and specificity in immunohistochemistry, cell immunofluorescence and protein immunoblotting.The monoclonal antibody screened in the present application can be used in the detection of tyrosine iodination modification of PP2A protein catalytic subunit 307, and provides support for tumor diagnosis, anti-tumor and neurological disease drug research and development.

The application belongs to the technical field of biological medicine, and particularly relates to an interfering peptide for regulating NR4A3 S280 phosphorylation, application thereof and a marker for liver cancer diagnosis. The interfering peptide is a sequence shown in SEQ ID NO. 1. The application proves that the interfering peptide can significantly restore the formation of the condensate of NR4A3, and further inhibit the progression of liver cancer in cell experiments and animal experiments. The targeted regulation of biomolecular condensate formation represents a promising oncology treatment approach, and the application provides a conceptual framework.

This invention belongs to the field of pharmaceutical technology and discloses the inhibitory effects and mechanisms of action of sclerotinib on lung cancer cells, cervical cancer cells, and ovarian cancer cells. Compared with the currently available broad-spectrum antitumor drug fluorouracil, sclerotinib exhibits superior antitumor properties. In-depth research revealed that sclerotinib acts on the novel protein STAT3 in cancer treatment, inhibiting STAT3 phosphorylation and preventing phosphonate-modified protein dimers from entering the cell nucleus to initiate transcription. Furthermore, sclerotinib inhibits the downstream anti-apoptotic protein BCL-2 of STAT3, synergistically inhibiting tumor cell proliferation. In this study, based on the half-maximal inhibitory concentration (IC50) results of sclerotinib against lung cancer cells A549, cervical cancer cells HeLa, and ovarian cancer cells A2780, we directly verified the anticancer target of sclerotinib through experiments, elucidated its anticancer mechanism, and provided theoretical and experimental basis for its entry into preclinical and clinical trials.